PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer
Status:
Terminated
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and the best dose of triciribine phosphate
when given together with paclitaxel, doxorubicin hydrochloride, and cyclophosphamide and to
see how well they work in treating patients with stage IIB-IV breast cancer. Triciribine
phosphate may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth. Drugs used in chemotherapy, such as paclitaxel, doxorubicin hydrochloride, and
cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing
the cells, by stopping them from dividing, or by stopping them from spreading. Giving
triciribine phosphate with paclitaxel, doxorubicin hydrochloride, and cyclophosphamide may be
a better treatment for breast cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Albert Einstein College of Medicine of Yeshiva University Prescient Therapeutics, Ltd.